Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 9, 2025The American Journal of Gastroenterology

Effectiveness and tolerability of bezafibrate in primary biliary cholangitis – a nationwide real-world study

View Full Paper
Ask AI
Bookmark
Share

Authors

MHMaria C. van HooffRVRozanne C. de VeerEWE. Werner

Discussion

Loading...

Member takes

Overview

Nationwide cohort study shows bezafibrate improves biochemical markers in primary biliary cholangitis, indicating substantial tolerability issues.

Key Points

  • Evaluate the real-world effectiveness and tolerability of bezafibrate in patients with primary biliary cholangitis.
  • Retrospective cohort study of patients initiating bezafibrate in Dutch PBC Cohort Study
  • Biochemical changes assessed during the first year of treatment
  • Dichotomous response evaluated using Paris II criteria
  • 317 individuals initiated bezafibrate therapy, with a median baseline ALP of 2.30
  • Cumulative cessation rate was 24.6% after 12 months, with 12.9% due to side effects
  • Normal ALP increased from 6% at baseline to 40% after one year

Cite This Study

Hooff et al. (2025) studied this question.

synapsesocial.com/papers/69401d682d562116f28f90c7https://doi.org/10.14309/ajg.0000000000003879
View Full Paper
Ask AI
Bookmark
Share